Oyster Therapeutics
Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.
$60MSeries A-2
ParticipantActivity from announced rounds
Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform